Immuno-Oncology | Specialty

The immuno-oncology condition center is a comprehensive resource for clinical news and expert insights on immuno-oncology. Read more at OncLive.

SCIB1/iSCIB1+ Vaccines Plus Checkpoint Inhibition Generates Immune Responses in Advanced Melanoma

July 22nd 2025

Among patients with advanced melanoma and the target HLA type—representing 80% of the study population—treatment with iSCIB1+ yielded an ORR of 69%.

FDA Issues CRL for RP1 Plus Nivolumab for Advanced Melanoma

July 22nd 2025

Five Under 5: Top Oncology Videos for the Week of 7/13

July 20th 2025

The top 5 OncLive videos of the week cover insights in ovarian cancer, RCC, melanoma, non–small cell lung cancer, and non–muscle-invasive bladder cancer.

Perioperative Nivolumab in Resectable NSCLC: Updated Data From CheckMate-77T

July 17th 2025

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss updated data from CheckMate-77T of perioperative nivolumab in resectable NSCLC.

How Immunotherapy Is Affecting Perioperative Treatment Decisions in Early-Stage NSCLC

July 17th 2025

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss how immunotherapy is affecting perioperative treatment in early-stage non–small cell lung cancer.

Five Under 5: Top Oncology Videos for the Week of 7/6

July 13th 2025

The top 5 OncLive videos of the week cover insights in ovarian cancer, RCC, melanoma, non–small cell lung cancer, and non–muscle-invasive bladder cancer.

Bria-IMT Plus Checkpoint Inhibition Leads to 52% 1-Year OS Rate in Heavily Pretreated Metastatic Breast Cancer

July 8th 2025

Bria-IMT plus checkpoint inhibition displayed a potential overall survival benefit in heavily pretreated, hormone receptor–positive breast cancer.

PAOLA-1 Analysis Shows PD-L1 Expression Correlates With HRD Positivity in High-Grade Serous Ovarian Cancer

July 7th 2025

PD-L1 expression was more common in HRD-positive high-grade serous ovarian cancer, indicating potential prognostic value in newly diagnosed cases.

Five Under 5: Top Oncology Videos for the Week of 6/29

July 6th 2025

The top 5 OncLive videos of the week cover insights in myelofibrosis, AL amyloidosis, pancreatic cancer, and PIK3CA-mutated breast cancer.

Nivolumab/Ipilimumab Maintains OS, ORR Benefits in Chinese Patients With Unresectable HCC

July 4th 2025

Nivolumab plus ipilimumab maintained an ORR benefit across subgroups of Chinese patients with unresectable hepatocellular carcinoma.

Nivolumab Plus Ipilimumab Improves HRQOL Vs Nivolumab Alone in MSI-H/dMMR mCRC

July 3rd 2025

CheckMate 8HW data show ipilimumab plus nivolumab improved PFS vs nivolumab alone while maintaining HRQOL.

Perioperative Durvalumab/FLOT Does Not Diminish PROs in Resectable Gastric/GEJ Adenocarcinoma

July 3rd 2025

Durvalumab plus FLOT did not lead to differences in patient-reported outcomes vs placebo plus FLOT in resectable gastric/GEJ cancer.

Emerging Immunotherapy Platforms Set to Redefine Melanoma Management Beyond the Frontline

July 3rd 2025

Douglas B. Johnson, MD, MSCI, discusses clinical questions, unmet needs, and exciting therapeutic developments with immuno-oncology in melanoma.

Invikafusp Alfa Generates Antitumor Activity in PD-(L)1–Resistant and –Naive, Antigen-Rich GI Tumors

July 2nd 2025

Invikafusp alfa produced responses as a single agent in antigen-rich gastrointestinal tumors, including metastatic colorectal cancer.

OncLive’s FDA Approval Report: The Regulatory Rundown for June 2025

July 1st 2025

Here is your guide to all therapeutic options that were cleared by the FDA in June 2025 spanning tumor types.

Perioperative IMNN-001 Utilizes Novel Delivery Route in Advanced Ovarian Cancer

July 1st 2025

Premal Thaker, MD, discusses findings for IMNN-001 plus perioperative chemotherapy in up-front, advanced ovarian cancer.

Zelenectide Pevedotin Plus Pembrolizumab Is Safe and Active in Treatment-Naive, Cisplatin-Ineligible Advanced Urothelial Cancer

June 30th 2025

The combination of zelenectide pevedotin and pembrolizumab was safe and produced antitumor activity in cisplatin-ineligible urothelial cancer.

Advances in Immunotherapy Necessitate Nuanced Understanding of Clinical Application Across Tumor Types

June 26th 2025

Douglas B. Johnson, MD, MSCI, discusses the importance of Cancer Immunotherapy Awareness Month and the utility of immunotherapy across tumor types.

Dr Johnson on Treatment Gaps With Immunotherapy in Melanoma

June 25th 2025

Douglas B. Johnson, MD, MSCI, highlighted avenues for improving immunotherapy use in melanoma during Cancer Immunotherapy Awareness Month.

Pembrolizumab Plus Chemoradiation Hits ORR End Point in Unresectable Vulvar Cancer

June 20th 2025

Pembrolizumab plus chemoradiation with maintenance pembrolizumab was safe and effective in unresectable vulvar cancer.